The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Viracept nelfinavir | Roche Registration Ltd. | HIV Infections | 🇪🇺 EU 1998-01-22 | Order → |
| Cerezyme imiglucerase | Sanofi B.V. | Gaucher Disease | 🇪🇺 EU 1997-11-17 | Order → |
| Daquiran pramipexole | Dr. Karl Thomae GmbH | Parkinson Disease | 🇪🇺 EU 1997-10-27 | Order → |
| Sifrol pramipexole | Boehringer Ingelheim International GmbH | Restless Legs Syndrome; Parkinson Disease | 🇪🇺 EU 1997-10-13 | Order → |
| BeneFIX nonacog alfa | Pfizer Europe MA EEIG | Hemophilia B | 🇪🇺 EU 1997-08-27 | Order → |
| Tasmar tolcapone | Viatris Healthcare Limited | Parkinson Disease | 🇪🇺 EU 1997-08-27 | Order → |
| Aprovel irbesartan | Sanofi Winthrop Industrie | Hypertension | 🇪🇺 EU 1997-08-26 | Order → |
| Karvea irbesartan | Sanofi Winthrop Industrie | Hypertension | 🇪🇺 EU 1997-08-26 | Order → |
| Helicobacter Test INFAI 13C-urea | INFAI, Institut für biomedizinische Analytik NMR-Imaging GmbH | Breath Tests; Helicobacter Infections | 🇪🇺 EU 1997-08-14 | Order → |
| Infanrix HepB diphtheria, tetanus, acellular pertussis and hepatitis B recombinant, adsorbed vaccine | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Tetanus; Immunization; Whooping Cough; Diphtheria | 🇪🇺 EU 1997-07-30 | Order → |
| NeoRecormon epoetin beta | Roche Registration GmbH | Kidney Failure, Chronic; Anemia; Cancer; Blood Transfusion, Autologous | 🇪🇺 EU 1997-07-16 | Order → |
| Revasc desirudin | Canyon Pharmaceuticals Ltd. | Venous Thrombosis | 🇪🇺 EU 1997-07-09 | Order → |
| Orlaam levacetylmethadol | Sipaco Internacional Lda. | Opioid-Related Disorders | 🇪🇺 EU 1997-07-01 | Order → |
| Cystagon mercaptamine bitartrate | Recordati Rare Diseases | Cystinosis | 🇪🇺 EU 1997-06-23 | Order → |
| Teslascan mangafodipir | GE Healthcare AS | Magnetic Resonance Imaging | 🇪🇺 EU 1997-05-22 | Order → |
| Liprolog insulin lispro | Eli Lilly and Company Limited | Diabetes Mellitus | 🇪🇺 EU 1997-05-07 | Order → |
| Vistide cidofovir | Gilead Sciences International Limited | Cytomegalovirus Retinitis | 🇪🇺 EU 1997-04-23 | Order → |
| Evotopin topotecan | Beecham Group plc | Ovarian Neoplasms | 🇪🇺 EU 1997-04-15 | Order → |
| Vitrasert Implant ganciclovir | Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH.. | Cytomegalovirus Retinitis; HIV Infections | 🇪🇺 EU 1997-03-18 | Order → |
| Avonex interferon beta-1a | Biogen Netherlands B.V. | Multiple Sclerosis | 🇪🇺 EU 1997-03-13 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.